AI Precision for Cardiovascular Health

AI Precision for Cardiovascular Health

We're building a solution to stop the world’s leading killer

Vascentis combines AI and biology to reshape cardiovascular care. By guiding clinicians to the right therapy for each patient, we aim to reduce risks, unlock efficiencies, and improve outcomes worldwide.

The Problem
The Problem
The Problem

Cardiovascular Desease: The #1 Killer

Cardiovascular Desease: the #1 Killer

Cardiovascular disease — including heart attacks, ischemic strokes, and other related conditions — remains the leading cause of death and disability globally.

Cardiovascular disease — including heart attacks, ischemic strokes, and other related conditions — remains the leading cause of death and disability globally.

0M+
0M+
0M+

Deaths in 2022 for cardiovascular disease

$0B
$0B
$0B

Direct care + productivity loss, 2018–2019

0M
0M
0M

People had some form of CVD between 2017-2020

0%
0%
0%

Of CVD deaths due to coronary heart disease

Our Solution
Our Solution

An AI-Driven Decision Support Platform

We turn complex cardiovascular data into clear, practical guidance, helping clinicians prescribe with confidence.

Built for Clinical Use

Designed to meet clinical standards and evaluate partient eligibility for advanced therapies.

Designed to meet clinical standards and evaluate partient eligibility for advanced therapies.

Actionable Insights

Provides clear recommendations and targeted test suggestions to confirm the best treatment path.

Provides clear recommendations and targeted test suggestions to confirm the best treatment path.

Our Solution
Our Solution

An AI-Driven Decision Support Platform

The Opportunity
The Opportunity
The Opportunity

Why Now?

Profits

Profits

Profits

Inefficiencies waiting to be optimized

Inefficiencies waiting to be optimized

Inefficiencies waiting to be optimized

The science is ready

Advanced therapies exist, pharmacogenomics is maturing, and AI is finally capable of integrating biology and data at scale. It's time to put these tools to work.

The market is ready

The cardiovascular health market is massive, but under-optimized. By enabling smarter decisions, we can save lives while unlocking billions in efficiency gains across healthcare systems and pharmaceutical pipelines.

Why This Team?
Why This Team?
Why This Team?

Biology + AI + FDA wins

Biology + AI + FDA wins

A rare combination of expertise in biology and AI, experienced in both pharmaceutical and device products requiring substantial FDA approval.

A rare combination of expertise in biology and AI, experienced in both pharmaceutical and device products requiring substantial FDA approval.

Andrew Buckler, PhD

Andrew Buckler, PhD

Andrew Buckler, PhD

Founder and Chief Executive Officer

Executive and scientist and serial entrepreneur

Executive and scientist and serial entrepreneur.

Multidisciplinarian at the intersection of cardiovascular biology, AI/ML, and systems pharmacology

Multidisciplinarian at the intersection of cardiovascular biology, AI/ML, and systems pharmacology.

Founder of Elucid, funded at $100M+ to phenotype CVD

Founder of Elucid, funded at $100M+ to phenotype CVD.

>70 peer reviewed publications and > 50 issued patents

>70 peer reviewed publications and > 50 issued patents.

Dr. Gregg W. Stone, MD, FACC, FSCAI

Dr. Gregg W. Stone, MD, FACC, FSCAI

Dr. Gregg W. Stone, MD, FACC, FSCAI

Founding Partner and Head of MAB

Cardiologist and Dir of Acad Affairs for Mt Sinai Heart and Prof. Med, Icahn School of Medicine

Cardiologist and Dir of Acad Affairs for Mt Sinai Heart and Prof. Med, Icahn School of Medicine

Cardiologist and Dir of Acad Affairs for Mt Sinai Heart and Prof. Med, Icahn School of Medicine.

PI for 150+ trials, 3000+ pubs, 1000s invited lectures.

PI for 150+ trials, 3000+ pubs, 1000s invited lectures.

H-index of 206, top 0.01% of cited on Web of Science.

H-index of 206, top 0.01% of cited on Web of Science.

Expert on drug-eluting stents and bioresorbable scaffolds

Expert on drug-eluting stents and bioresorbable scaffolds

Expert on drug-eluting stents and bioresorbable scaffolds.

Dr. Brajesh Lal, MD, MBBS, FACS

Dr. Brajesh Lal, MD, MBBS, FACS

Chief of Vascular Surgery, UMMC, Mayo, and VA. Co-chair of CREST-2.

Dr. Ulf Hedin, MD PhD

Dr. Ulf Hedin, MD PhD

Prof Vascular Surgery and Molecular Medicine, KI (Stockholm). PI of BiKE.

Dr. David Erlinge, MD PhD

Dr. David Erlinge, MD PhD

Head of Cardiology, Skane U (Lund) and Leader of CV trials including SCAPIS.

Dr. Patrick Serruys, MD PhD

Dr. Patrick Serruys, MD PhD

Prof Interventional Cardiology and Innovation, NUI and Imperial (London).

Clint Miller, PhD

Clint Miller, PhD

Functional genomics of complex cardiovascular diseases at Stanford/UVA.

Ian Kemp MBA MSF

Ian Kemp MBA MSF

Founding Partner and Chief Business Officer.

Let’s shape the future of cardiovascular health

Let’s shape the future of cardiovascular health

© 2025 Vascentis.